title: Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
abstract: Ursodeoxycholic acid (UDCA) is a steroid bile acid approved for primary biliary cirrhosis (PBC). UDCA is reported to have "hepato-protective properties". Yet, UDCA has "unanticipated" toxicity, pronounced by more than double number of deaths, and eligibility for liver transplantation compared to the control group in 28 mg/kg/day in primary sclerosing cholangitis, necessitating trial halt in North America. UDCA is associated with increase in hepatocellular carcinoma in PBC especially when it fails to achieve biochemical response (10 and 15 years incidence of 9% and 20% respectively). "Unanticipated" UDCA toxicity includes hepatitis, pruritus, cholangitis, ascites, vanishing bile duct syndrome, liver cell failure, death, severe watery diarrhea, pneumonia, dysuria, immune-suppression, mutagenic effects and withdrawal syndrome upon sudden halt. UDCA inhibits DNA repair, co-enzyme A, cyclic AMP, p53, phagocytosis, and inhibits induction of nitric oxide synthatase. It is genotoxic, exerts aneugenic activity, and arrests apoptosis even after cellular phosphatidylserine externalization. UDCA toxicity is related to its interference with drug detoxification, being hydrophilic and anti-apoptotic, has a long half-life, has transcriptional mutational abilities, down-regulates cellular functions, has a very narrow difference between the recommended (13 mg/kg/day) and toxic dose (28 mg/kg/day), and it typically transforms into lithocholic acid that induces DNA strand breakage, it is uniquely co-mutagenic, and promotes cell transformation. UDCA beyond PBC is unjustified.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo 11956, Egypt.
authors.forename: Magd A
authors.initials: MA
authors.lastname: Kotb
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D002756:Cholagogues and Choleretics / Q000009:adverse effects* / Q000627:therapeutic use; D003065:Coenzyme A / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004260:DNA Repair / Q000187:drug effects; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D008115:Liver Regeneration / Q000187:drug effects*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014580:Ursodeoxycholic Acid / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D002756:Cholagogues and Choleretics; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D014580:Ursodeoxycholic Acid; D000242:Cyclic AMP; D003065:Coenzyme A